News / Health

Race On to Develop New Antibiotics

Carbapenem-resistant Klebsiella pneumoniae bacteria
Carbapenem-resistant Klebsiella pneumoniae bacteria

Multimedia

Vidushi Sinha

Drug companies are struggling to develop new and more effective antibiotics to combat the growing worldwide threat from drug-resistant germs.  In this second of her 2-part report on "Battling Superbugs," we examine the looming public health danger, and the challenges drug companies face in bringing new antibiotics to market.

Medical experts watching the rising tide of drug-resistant bacteria have begun sounding the alarms.  They say life-threatening infections could jeopardize surgeries, cancer treatment, organ transplants, and many other specialized medical procedures.

And some warn that if new anti-microbial drugs are not developed within the next few years, billions of people will be left nearly defenseless against some lethal bacterial infections.

Such concerns have prompted the Infectious Disease Society of America (IDSA) to call for the development of 10 new antibiotic drugs by the year 2020, an initiative the group calls "10 by 20."

“The 10 by 20 initiative is IDSA’s challenge to the global community to come together to bring the right group of people together. People in government, industry, academia, policy makers to figure out the right combination of incentives that both will motivate companies who want to develop new antibiotics and also to find new ways to manage these products over time," said Robert Guidos, Vice President of IDSA.

Experts say that the hour of reckoning has arrived, and that if efforts to combat the problem are not launched now, dangerous diseases eradicated long ago could make a comeback.

Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, shared that concern recently with Capitol Hill lawmakers. "If we don't improve our response to the public health problem of antibiotic resistance, we may enter a post- antibiotic world in which we will have few or no clinical interventions for some infections," he said.

Recent studies have shown that there are very few new antibiotics in the development pipeline that would work against lethal infections born out of bacterial resistance such as Methicillin-resistant Staphylococcus aureus, commonly known as MRSA, or carbapenem-resistant Klebsiella pneumoniae, or CRKP for short.

About 2 million MRSA infections have been reported in U.S. hospitals each year since 2002.

Barry Eisenstein is Vice President of Cubist, an American drug company with a new anti-MRSA drug in development, as well as many others.

He says neither the federal regulatory environment nor the pharmaceutical market are favorable for companies trying to develop antibiotics. “The expense and difficulty of doing these...trials for the most important diseases have become very hard and very difficult to the point that many of the big companies have actually gotten out of the field of antibiotic development because they don’t feel that it’s worth the investment," he said.

Some drug company executives contend that financial returns on investments made in a new antibiotic are significantly lower than for other new drugs reaching the market.

“Think about the cholesterol-lowering drug - it’s not uncommon for many of the statins to be bringing in $5 - 10 or more billions per year. For an antibiotic to sell at a half a billion is considered a blockbuster, almost unheard of," he said.

Eisenstein says the push to make "a perfect drug" that is both safe and effective beyond a shadow of doubt has considerably slowed the pace of new antibiotics reaching the market.

To get companies back in the antibiotics game, Eisenstein says two things have to be done.

“The regulatory risk - to decrease the great hurdles to get approval and increase the likelihood of being able to get a drug approved in a shorter period of time, at a higher proportion of probability. And then on the economic side, to enable the companies to have greater incentives to overcome what we call market failure," he said.

Drug companies note that the newest antibiotics, typically, are likely to be prescribed more carefully and used more sparingly - meaning slower sales and smaller profits for the companies that develop them.

Neverthless, public health experts say one new antibiotic has already been approved for use in the United States, and they are hopeful that the ambitious goal  of developing nine more by 2020 can be achieved.

You May Like

At International AIDS Conference One Goal, Many Paths

The 12,000 delegates attending 20th International AIDS Conference in Melbourne have vastly different visions about how to eradicate disease More

Disasters May Doom Malaysia’s Flag Carrier

Even before loss of two jets loaded with passengers on international flights, company had been operating in red for three years, accumulating deficit of $1.3 billion More

Afghan Presidential Vote Audit Continues Despite Glitches

Process has been marred by walkouts by representatives of two competing candidates, Abdullah Abdullah and Ashraf Ghani More

This forum has been closed.
Comments
     
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Nature of Space Exploration Enters New Agei
X
Elizabeth Lee
July 20, 2014 2:36 AM
Forty-five years ago this month, the first humans walked on the moon. It was during an era of the space race between the United States and the Soviet Union. World politics have changed since then and -- as Elizabeth Lee reports -- so has the nature of space exploration.
Video

Video Nature of Space Exploration Enters New Age

Forty-five years ago this month, the first humans walked on the moon. It was during an era of the space race between the United States and the Soviet Union. World politics have changed since then and -- as Elizabeth Lee reports -- so has the nature of space exploration.
Video

Video Chicago’s Argonne Lab Developing Battery of the Future

In 2012, the U.S. Department of Energy’s Office of Science awarded a $120 million grant to a new technology center focused on battery development - headquartered at Argonne National Laboratory in suburban Chicago, Illinois. As VOA’s Kane Farabaugh reports, there scientists are making the next technological breakthroughs in energy storage.
Video

Video In NW Pakistan, Army Offensive Causes Massive Number of Displaced

Pakistan’s army offensive in North Waziristan has resulted in the large-scale displacement of the local population. VOA's Ayaz Gul reports from northwest Pakistan where authorities say around 80 percent of the estimated 1 million internally displaced persons [IDPs] have settled in Bannu district, while much of the remaining 20 percent are scattered in nearby cities.
Video

Video Kurdish Peshmerga Force Secures Kirkuk, Its Oil

The Kurdistan regional government has sent its Peshmerga troops into the adjacent province of Kirkuk to drive out insurgents, and to secure the area's rich oil fields. By doing this, the regional government has added a fourth province to the three it officially controls. The oil also provides revenue that could make an independent Kurdistan economically strong. VOA’s Jeffrey Young went out with the Peshmerga and filed this report.
Video

Video Malaysia Reeling: Second Air Disaster in Four Months

Malaysia is reeling from the second air disaster in four months involving the country’s flag carrier. Flight 340 vanished in March and despite an extensive search, no debris has been found. And on Thursday, Flight 17, likely hit by a surface-to-air missile, came apart over eastern Ukraine. The two incidents together have left more than 500 people dead. VOA Correspondent Steve Herman reports from Kuala Lumpur.
Video

Video Diplomatic Crisis Grows Over MH17 Plane Crash

The Malaysia Airlines crash in eastern Ukraine is drawing reaction from leaders around the world. With suspicions growing that a surface-to-air missile shot down the aircraft, there are increasing tensions in the international community over who is to blame. Henry Ridgwell reports for VOA from London.
Video

Video Undocumented Immigrants Face Perilous Journey to US, No Guarantees

Every day, hundreds of undocumented immigrants from Central America attempt the arduous journey through Mexico and turn themselves over to U.S. border patrol -- with the hope that they will not be turned away. But the dangers they face along the way are many, and as Ramon Taylor reports from the Rio Grande Valley in Texas, their fate rests on more than just the reception they get at the US border.
Video

Video Scientists Create Blackest Material Ever

Of all the black things in the universe only the infamous "black holes" are so black that not even a tiny amount of light can bounce back. But scientists have managed to create material almost as black, and it has enormous potential use. VOA’s George Putic has more.
Video

Video Fog Collector Transforming Maasai Water Harvesting in Kenya

The Maasai people of Kenya are known for their cattle-herding, nomadic lifestyle. But it's an existence that depends on access to adequate water for their herds and flocks. Lenny Ruvaga reports for VOA, on a "fog collector."

AppleAndroid